SALT LAKE CITY--(BUSINESS WIRE)--Tolero Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing treatments for oncology and hematologic diseases, announced today that it will present two poster presentations at the 21st European Hematology Association (EHA) Congress in Copenhagen, Denmark, June 9 through 12, 2016. The presentations focus on Tolero’s development of cyclin-dependent kinase-9 (CDK9) inhibitors as a novel strategy to target acute myeloid disorders.
The first presentation describes the highly synergistic activity of combining a CDK9 inhibitor (alvocidib) with the B-cell lymphoma 2 (BCL-2) inhibitor, venetoclax (ABT-199) in models of acute myeloid leukemia (AML) through a mechanism that involves targeting MCL-1 expression. The subject of the second presentation is the discovery and development of TP-1287, a prodrug of alvocidib, for oral delivery in preclinical development. The findings to be reported in both of these presentations are significant milestones for the progression of the overall CDK9 inhibitor program at Tolero.
Details of the poster presentations are as follows:
Abstract Code: P557
Title: Alvocidib Potentiates the Activity of
ABT-199 in Nonclinical Models of Acute Myeloid Leukemia
Presenter:
Dr. Clifford Whatcott
Session Title: Acute myeloid leukemia -
Biology 3
Date: Saturday, June 11, 2016
Presentation Time:
17:30 PM-19:00 PM CEST
Location: Poster area (Hall H)
Abstract Code: E891
Title: TP-1287, An Oral Prodrug of the
Cyclin-Dependent Kinase-9 Inhibitor Alvocidib
Presenter: E-Poster
Session
Title: Acute myeloid leukemia - Biology
Date: E-poster viewing is
available throughout the Congress
About Alvocidib
Alvocidib is a potent, small-molecule inhibitor of
cyclin-dependent kinase-9 (CDK9) in development as a combination therapy
for relapsed/refractory acute myeloid leukemia (AML). CDK9 is a protein
critical to the regulation of gene expression including the MCL-1 gene
and other important genes involved in cancer. Given the key role CDK9
de-regulation plays in expression of cancer-associated genes related to
cell division and proliferation, CDK9 is an attractive target for the
treatment of various cancers.
About Tolero
Tolero Pharmaceuticals is a clinical stage
biopharmaceutical company developing treatments to improve and extend
the lives of patients with cancer and blood diseases. Our diverse
pipeline targets important biological drivers of blood disorders to
treat leukemias and anemia as well as important targets of drug
resistance and transcriptional control.
Contacts
Tolero Pharmaceuticals, Inc.
Joe Nilson, 801-285-6003
bizdev@toleropharma.com
